Literature DB >> 21211639

Mechanisms of allergen-specific immunotherapy.

Cezmi A Akdis1, Mübeccel Akdis.   

Abstract

Allergen-specific immunotherapy has been used for 100 years as a desensitizing therapy for allergic diseases and represents the potentially curative and specific method of treatment. The mechanisms of action of allergen-specific immunotherapy include the very early desensitization effects, modulation of T-and B-cell responses and related antibody isotypes, and migration of eosinophils, basophils, and mast cells to tissues, as well as release of their mediators. Regulatory T (Treg) cells have been identified as key regulators of immunologic processes in peripheral tolerance to allergens. Skewing of allergen-specific effector T cells to a regulatory phenotype appears as a key event in the development of healthy immune response to allergens and successful outcome in patients undergoing allergen-specific immunotherapy. Naturally occurring forkhead box protein 3-positive CD4(+)CD25(+) Treg cells and inducible T(R)1 cells contribute to the control of allergen-specific immune responses in several major ways, which can be summarized as suppression of dendritic cells that support the generation of effector T cells; suppression of effector T(H)1, T(H)2, and T(H)17 cells; suppression of allergen-specific IgE and induction of IgG4; suppression of mast cells, basophils, and eosinophils; and suppression of effector T-cell migration to tissues. New strategies for immune intervention will likely include targeting of the molecular mechanisms of allergen tolerance and reciprocal regulation of effector and Treg cell subsets. Copyright Â
© 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21211639     DOI: 10.1016/j.jaci.2010.11.030

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  114 in total

Review 1.  Assessing basophil functional measures during monoclonal anti-IgE therapy.

Authors:  Sarbjit S Saini; Donald W MacGlashan
Journal:  J Immunol Methods       Date:  2012-06-01       Impact factor: 2.303

Review 2.  Innate and adaptive immune responses in asthma.

Authors:  Stephen T Holgate
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

3.  Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses.

Authors:  Ravi K Viswanathan; William W Busse
Journal:  Chest       Date:  2012-05       Impact factor: 9.410

Review 4.  [Immunological mechanisms of allergen-specific immunotherapy].

Authors:  J-P Allam; N Novak
Journal:  Hautarzt       Date:  2017-04       Impact factor: 0.751

5.  Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice.

Authors:  Mike Kulis; Balachandra Gorentla; A Wesley Burks; Xiao-Ping Zhong
Journal:  Mol Nutr Food Res       Date:  2013-02-05       Impact factor: 5.914

Review 6.  Novel approaches to food allergy.

Authors:  Yao-Hsu Yang; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2014-06       Impact factor: 8.667

Review 7.  Recombinant allergens: the present and the future.

Authors:  Marek Jutel; Katarzyna Solarewicz-Madejek; Sylwia Smolinska
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 8.  Adjuvants for allergy vaccines.

Authors:  Philippe Moingeon
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

Review 9.  Immunoglobulin E-binding epitopes of mite allergens: from characterization to immunotherapy.

Authors:  Yubao Cui
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 10.  The identification of potentially pathogenic and therapeutic epitopes from common human allergens.

Authors:  Véronique Schulten; Carla Oseroff; Rafeul Alam; David Broide; Pandurangan Vijayanand; Bjoern Peters; Alessandro Sette
Journal:  Ann Allergy Asthma Immunol       Date:  2012-11-15       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.